CRISPR/Cas9 Gene Editing in Hepatocellular Carcinoma: Current Progress and Future Perspectives

Hanyu Zheng

2025

Abstract

The use of CRISPR/Cas9 gene-editing technology to treat viral hepatitis and hepatocellular carcinoma (HCC) is examined in this paper. HCC, a deadly cancer with high incidence, poses significant challenges due to late diagnosis and aggressive progression. CRISPR/Cas9 offers promising avenues for treatment by targeting genetic mutations, oncogenes, and viral genomes. The technology's ability to disrupt HBV's cccDNA and silence HCV RNA highlights its potential in viral hepatitis therapy. In HCC, CRISPR/Cas9 can suppress tumor growth by correcting mutations in critical genes like TP53 and CTNNB1. Obstacles to clinical translation, however, include immunological reactions, off-target effects, and delivery efficiency. The document emphasizes the need for advancements in delivery systems, specificity improvements, and ethical considerations to unlock CRISPR/Cas9's full potential in precision medicine.

Paper Citation

in Harvard Style

Zheng H. (2025). CRISPR/Cas9 Gene Editing in Hepatocellular Carcinoma: Current Progress and Future Perspectives. In Proceedings of the 1st International Conference on Biomedical Engineering and Food Science - Volume 1: BEFS; ISBN 978-989-758-789-4, SciTePress, pages 241-247. DOI: 10.5220/0014465900004933

in Bibtex Style

@conference{befs25,
author={Hanyu Zheng},
title={CRISPR/Cas9 Gene Editing in Hepatocellular Carcinoma: Current Progress and Future Perspectives},
booktitle={Proceedings of the 1st International Conference on Biomedical Engineering and Food Science - Volume 1: BEFS},
year={2025},
pages={241-247},
publisher={SciTePress},
organization={INSTICC},
doi={10.5220/0014465900004933},
isbn={978-989-758-789-4},
}

in EndNote Style

TY - CONF

JO - Proceedings of the 1st International Conference on Biomedical Engineering and Food Science - Volume 1: BEFS
TI - CRISPR/Cas9 Gene Editing in Hepatocellular Carcinoma: Current Progress and Future Perspectives
SN - 978-989-758-789-4
AU - Zheng H.
PY - 2025
SP - 241
EP - 247
DO - 10.5220/0014465900004933
PB - SciTePress